PTGX
NASD Protagonist Therapeutics, Inc.$142.44 ↑ +0.00 (+0.00%) Trading Up from the previous close of $142.44, $1.25 below the day’s high of $143.69
- YTD change
- +63.09%
- vs 20-day SMA
- -1.50%
- vs 200-day SMA
- +29.46%
Price ranges
Price & Performance
+42.57 (+42.63%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 11.4% away from all-time highs of $160.81
- PTGX is up 63% since the beginning of the year
- PTGX is up 111% over the past 12 months
- PTGX is down 5% over the past 1 month
- 12% of all PTGX investors are betting against PTGX
PTGX reads very good: price sits above one of the two key moving averages, the 12-month move is +118.7%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -0.39%
- vs 8-day SMA
- +0.18%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
